Project Portfolio – Pandora Endocrine Innovation B.V. (PEI)

1. Women’s Health (WH)

Contraception

1.1 Oral contraception without progestins (NOPANTE)*

On May 30, 2023 the leading scientific journal dealing with basic and clinical breast cancer research “Breast Cancer Research (BCR)” published the Perspective Review paper “Progesterone from ovulatory menstrual cycles is an important cause of breast cancer” by Herjan J.T. Coelingh Bennink, Iman J. Schultz, Marcus Schmidt, V. Craig Jordan, Paula Briggs, Jan F.M. Egberts, Kristina Gemzell-Danielsson, Ludwig Kiesel, Kirsten Kluivers, Jan Krijgh, Tommaso Simoncini, Frank Z. Stanczyk and Robert D. Langer.

The most important message of this narrative review paper is that progesterone from normal menstrual cycles causes most BCs, whereas estrogens and androgens may stimulate existing hormone receptor positive BC, but do not cause BC. Four authors of this paper are related to Pantarhei (HCB, IJS, JFME and JK) and the other nine authors are experts in the field of Reproductive Endocrinology and Oncology, supporting this rather thought-provoking paper, that will hopefully lead to a reappraisal and a turnaround of the medical view and opinion on the cause of breast cancer and change the negative perception of estrogens.

1.2 Oral hormonal male contraception (MANTE) *

Infertility

1.3 Improvement of embryo implantation during IVF (VABIO)*

Pregnancy

1.4 Induction of term labor (ARBOR1 project)

1.5 Inhibition of preterm labor (ARBOR2 project)

1.6 Prevention of Gestational Diabetes (GD)

Menopausal Hormone Therapy (MHT)

1.7 MHT without progestins (NOPAIE)

1.8 Multiple Sclerosis, method undisclosed

1.9 Alzheimer’s disease, method undisclosed

2. Endocrine treatment of COVID-19

2.1 ADET (Androgen Deprivation and Estrogen Therapy)* for COVID-19 (Co-Treatment of Androgen Deprivation Therapy (ADT) with a GnRH analogue and High Dose Estrogen (HDE) for serious SARS-CoV-2 disease

See Research Letter European Urology (2021) and Paper in Heliyon (2022).

3. SUBOX (sublingual / buccal, thermostable, oxytocin)

3.1 Effect SUBOX on Duchenne muscular dystrophy (DMD) *

3.2 Effect SUBOX on sarcopenia*

3.3 Effect SUBOX on obesity*

3.4 SUBOX vs Nolasiban (anti-oxytocin) in Anorexia Nervosa (AN)*

4. Reproductive Endocrine Oncology (REO)

4.1 WNT4 immunization to prevent/treat breast cancer (BC)*

4.2 Induction of estrogen receptors in triple negative breast cancer (TNBC)

4.3 New regimen for ER+ HER- advanced BC

4.4 High Dose Estrogen** for advanced prostate cancer (PC) *

4.5 High Dose Estrogen ** for advanced BC*

*   Patent application submitted or ready for submission

** Undisclosed new estrogen (not estetrol E4)